{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:35Z","timestamp":1784347415139,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106772","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:12:01Z","timestamp":1758604321000},"page":"106772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-9071","authenticated-orcid":false,"given":"Vincent","family":"Brochard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Le Vavasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvine","family":"Pinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Bourneau Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Boudot de la Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Chaugne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106772_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by Ocrelizumab","volume":"11","author":"Baird-Gunning","year":"2020","journal-title":"Neurohospitalist"},{"issue":"1","key":"10.1016\/j.msard.2025.106772_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/13524585231206218","article-title":"Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab","volume":"30","author":"Beigneux","year":"2024","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"issue":"9","key":"10.1016\/j.msard.2025.106772_bib0003","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"issue":"182","key":"10.1016\/j.msard.2025.106772_bib0004","first-page":"17","article-title":"International ethical guidelines for biomedical research involving human subjects","year":"2002","journal-title":"Bull. Med. Ethics"},{"key":"10.1016\/j.msard.2025.106772_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103357","article-title":"Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: prevalence, predicting factors and clinical outcomes","volume":"57","author":"Dinoto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106772_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18_supplement","key":"10.1016\/j.msard.2025.106772_bib0007","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1212\/WNL.98.18_supplement.2481","article-title":"Long-term safety of Ofatumumab in patients with relapsing multiple sclerosis (S14.004)","volume":"98","author":"Hauser","year":"2022","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.msard.2025.106772_bib0008","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106772_bib0009","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejim.2006.05.002","article-title":"Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment","volume":"17","author":"Klepfish","year":"2006","journal-title":"Eur. J. Intern. Med."},{"issue":"2","key":"10.1016\/j.msard.2025.106772_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/iji.12614","article-title":"Genetic variations in low-to-medium-affinity fc\u03b3 receptors and autoimmune neutropenia in early childhood in a Danish cohort","volume":"50","author":"Kl\u00f8ve-Mogensen","year":"2023","journal-title":"Int. J. Immunogenet."},{"issue":"10","key":"10.1016\/j.msard.2025.106772_bib0011","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","article-title":"Chronic neutropenia mediated by fas ligand","volume":"95","author":"Liu","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.msard.2025.106772_bib0012","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1007\/s10072-021-05379-9","article-title":"Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106772_bib0013","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106772_bib0014","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428190600649349","article-title":"Late-onset neutropenia following rituximab","volume":"47","author":"McLaughlin","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.msard.2025.106772_bib0015","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2025.106772_bib0016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in primary progressive Multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106772_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105147","article-title":"Neutropaenia complications from Ocrelizumab and Rituximab treatment","volume":"81","author":"Pang","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106772_bib0019","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.msard.2025.106772_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Rep."},{"issue":"7","key":"10.1016\/j.msard.2025.106772_bib0021","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","article-title":"Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia","volume":"22","author":"Stamatopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.msard.2025.106772_bib0022","author":"Tauro"},{"issue":"6","key":"10.1016\/j.msard.2025.106772_bib0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12032-021-01516-8","article-title":"The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas","volume":"38","author":"Tesfa","year":"2021","journal-title":"Med. Oncol. Northwood L. Engl"},{"issue":"5","key":"10.1016\/j.msard.2025.106772_bib0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine"},{"key":"10.1016\/j.msard.2025.106772_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"409","author":"Zanetta","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2025.106772_bib0027","first-page":"494","article-title":"An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia","volume":"20","author":"Zhang","year":"2022","journal-title":"Arch. Med. Sci."},{"issue":"2","key":"10.1016\/j.msard.2025.106772_bib0028","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late-onset neutropenia from Rituximab for autoimmune disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthrit. Rheumatol. Hob. NJ"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:36:14Z","timestamp":1784345774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"alternative-id":["S2211034825005140"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106772","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106772"}}